Predictive autoimmunity using autoantibodies: screening for anti-nuclear antibodies
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Early detection of antinuclear antibodies (ANA) in asymptomatic subjects is useful to predict autoimmune diseases years before diagnosis. ANA have been determined by indirect immunofluorescence (IIF) using human epithelial type 2 (HEp-2) cells, which is considered the gold standard technique. Multiplex technology (BioPlex ANA Screen) has been introduced for ANA evaluation in recent years. Nevertheless, concordance between BioPlex and IIF is low and there is no harmonization between both methods for detection of autoantibodies. This study has aimed to clarify the clinical significance of autoantibodies detected by BioPlex ANA Screen in subjects with undiagnosed clinical suspicion of autoimmune disease and to determine the predictive value of autoantibodies detected by BioPlex ANA Screen. Methods: A 3-year follow-up study was performed of 411 subjects without a clear diagnosis of autoimmune diseases in whom autoantibodies were detected by BioPlex ANA Screen that were negative by IIF on HEp-2 cells. Results: At 3 years of follow-up, 312 (76%) subjects were positive for autoantibodies by IIF and 99 subjects continued to be negative. A diagnosis of autoimmune disease was found in most of the subjects (87%). Conclusions: BioPlex ANA Screen has greater sensitivity than IIF on HEp-2 cells for autoantibodies detection. Early detection of these antibodies by BioPlex can predict possible development of autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pludowski, P., Holick, M. F., Pilz, S., Wagner, C. L., Hollis, B. W., Grant, W. B., Shoenfeld, Y., Lerchbaum, E., Llewellyn, D. J., Kienreich, K., et al. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.02.004 · Cited by 836
Self-citationAgmon-Levin, N., Damoiseaux, J., Kallenberg, C., Sack, U., Witte, T., Herold, M., Bossuyt, X., Musset, L., Cervera, R., Plaza-Lopez, A., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203863 · Cited by 615
Self-citation
Cited by
Mummert, E., Fritzler, M. J., Sjöwall, C., Bentow, C., & Mahler, M. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.05.014 · Cited by 86
Standardization and harmonization of autoimmune diagnostics
Jacobs, J. F. M., & Bossuyt, X. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0807 · Cited by 31
“This is an important study that shows that BioPlex detects autoantibodies earlier than IIF and that these antibodies may be an early predictor for the emergence of autoimmune disease [22].”
BackgroundInfantino, M., Manfredi, M., Merone, M., Grossi, V., Benucci, M., Li Gobbi, F., Bandinelli, F., Damiani, A., & Soda, P. (2018) · Immunologic Research · doi:10.1007/s12026-018-8992-9 · Cited by 16
Metadata
- Authors
- Pérez, D., Gilburd, B., Cabrera-Marante, Ó., Martínez-Flores, J. A., Serrano, M., Naranjo, L., Pleguezuelo, D., Morillas, L., Shovman, O., Paz-Artal, E., Shoenfeld, Y., & Serrano, A.
- Venue
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Publisher
- Walter de Gruyter GmbH
- Published
- 2017-06-17
- Volume
- 56
- Issue
- 10
- Pages
- 1771-1777
- ISSN
- 1434-6621 (ISSN-L)
- 1437-4331
- OpenAlex
- W2691441091
- Cited by
- 38
- References
- 2
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predictive autoimmunity using autoantibodies: screening for anti-nuclear antibodies. https://app.cochat.ai/papers/10.1515/cclm-2017-0241
- The paper
- Pérez, D., Gilburd, B., Cabrera-Marante, Ó., Martínez-Flores, J. A., Serrano, M., Naranjo, L., Pleguezuelo, D., Morillas, L., Shovman, O., Paz-Artal, E., Shoenfeld, Y., & Serrano, A. (2018). Predictive autoimmunity using autoantibodies: screening for anti-nuclear antibodies. Clinical Chemistry and Laboratory Medicine (CCLM). https://doi.org/10.1515/cclm-2017-0241
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.